Xtl Biopharmaceuticals (XTLB) Cash from Operations (2009 - 2024)

Xtl Biopharmaceuticals (XTLB) posted quarterly Cash from Operations of 303000.0 for Q4 2024, up 40.35% on a QoQ basis from 508000.0 in Q2 2016.

Xtl Biopharmaceuticals (XTLB) Cash from Operations (2009 - 2024) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported Cash from Operations for 9 consecutive years, with 303000.0 the latest figure, recorded in Q4 2024.

Quarterly Cash from Operations changed N/A year-over-year to 303000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 303000.0 (changed N/A YoY) and the FY2025 annual result came in at 1025000.0, up 36.65% from the prior year.
Cash from Operations improved to 303000.0 in Q4 2024 per XTLB's latest filing, from 508000.0 in the prior quarter.
Over the last five years, Cash from Operations for XTLB reached as high as 303000.0 in Q4 2024 and fell as low as 303000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Operations (Qtr)
1	Oculis Holding AG	66,921.77 Bn	66,921.49 Bn	-	-19.59 Mn
2	Nanobiotix	1,933.35 Bn	1,933.29 Bn	-	-
3	Akari Therapeutics	1,063.56 Bn	1,063.56 Bn	-	-2.49 Mn
4	BeOne Medicines	468.54 Bn	463.75 Bn	1.35 Bn	201.34 Mn
5	Vertex Pharmaceuticals	123.45 Bn	116.20 Bn	2.59 Bn	1.43 Bn
6	Regeneron Pharmaceuticals	70.42 Bn	61.67 Bn	3.31 Bn	1.08 Bn
7	Belite Bio	63.57 Bn	63.57 Bn	-	-
8	Argenx Se	55.83 Bn	50.65 Bn	1.41 Bn	-
9	Alnylam Pharmaceuticals	37.75 Bn	34.74 Bn	959.66 Mn	70.50 Mn
10	Xtl Biopharmaceuticals	2.51 Bn	2.51 Bn	-	-

Download Data